Meridian Bioscience

Meridian Bioscience EBITDA Margin

The EBITDA Margin of Meridian Bioscience (VIVO) as of Oct 27, 2026 is 22.70 %. In the previous year, EBITDA Margin was 32.03 % — a change of -29.13% (lower).

EBITDA Margin

22.70 %

YoY

-29.13%

Last updated:

EBITDA Margin of Meridian Bioscience is 2022 22.70 % . EBITDA Margin of Meridian Bioscience was 2021 32.03 % . It decreases by -29.13% lower compared to the previous year.

The Meridian Bioscience EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2015
28.80 USD
Jan 1, 2016
27.33 USD
Jan 1, 2017
22.31 USD
Jan 1, 2018
20.93 USD
Jan 1, 2019
19.35 USD
Jan 1, 2020
26.80 USD
Jan 1, 2021
32.03 USD
Jan 1, 2022
22.70 USD
The Meridian Bioscience EBITDA Margin history
YEAREBITDA MarginYoY
22.70 %-29.13%
32.03 %+19.50%
26.80 %+38.50%
19.35 %-7.52%
20.93 %-6.20%
22.31 %-18.37%
27.33 %-5.09%
28.80 %+3.76%
27.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

EBITDA Margin of Meridian Bioscience is 22.70 % in 2022.

EBITDA Margin of Meridian Bioscience changed from 32.03 % to 22.70 %, representing a -29.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Meridian Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Meridian Bioscience

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Meridian Bioscience